STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke.

Abstract

BACKGROUND AND PURPOSE:

Symptomatic intracerebral hemorrhage (sICH) is a rare but the most feared complication of intravenous thrombolysis for ischemic stroke. We aimed to develop and validate a nomogram for individualized prediction of sICH in intravenous thrombolysis-treated stroke patients included in the multicenter SITS-ISTR (Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register).

METHODS:

All patients registered in the SITS-ISTR by 179 Italian centers between May 2001 and March 2016 were originally included. The main outcome measure was sICH per the European Cooperative Acute Stroke Study II definition (any type of intracerebral hemorrhage with increase of ≥4 National Institutes of Health Stroke Scale score points from baseline or death <7 days). On the basis of multivariate logistic model, the nomogram was generated. We assessed the discriminative performance by using the area under the receiver-operating characteristic curve and calibration of risk prediction model by using the Hosmer-Lemeshow test.

RESULTS:

A total of 15 949 patients with complete data for generating the nomogram was randomly dichotomized into training (3/4; n=12 030) and test (1/4; n=3919) sets. After multivariate logistic regression, 10 variables remained independent predictors of sICH to compose the STARTING-SICH (systolic blood pressure, age, onset-to-treatment time for thrombolysis, National Institutes of Health Stroke Scale score, glucose, aspirin alone, aspirin plus clopidogrel, anticoagulant with INR ≤1.7, current infarction sign, hyperdense artery sign) nomogram. The area under the receiver-operating characteristic curve of STARTING-SICH was 0.739. Calibration was good (P=0.327 for the Hosmer-Lemeshow test).

CONCLUSIONS:

The STARTING-SICH is the first nomogram developed and validated in a large SITS-ISTR cohort for individualized prediction of sICH in intravenous thrombolysis-treated stroke patients.

• Authors: Manuel Cappellari, Gianni Turcato, Stefano Forlivesi, Cecilia Zivelonghi, Paolo Bovi, Bruno Bonetti, Danilo Toni
• Journal: Stroke (Stroke) Vol. 49 Issue 2 Pg. 397-404 (02 2018) ISSN: 1524-4628 [Electronic] United States
• PMID: 29311264 (Publication Type: Journal Article)
• Copyright: © 2018 American Heart Association, Inc.

Chemical References

• Fibrinolytic Agents
• Clopidogrel
• Tissue Plasminogen Activator
• Ticlopidine
• Aspirin

Topics

• Aged
• Aged, 80 and over
• Aspirin (therapeutic use)
• Brain Ischemia (drug therapy)
• Cerebral Hemorrhage (etiology)
• Clopidogrel
• Female
• Fibrinolytic Agents (therapeutic use)
• Humans
• Male
• Middle Aged
• Nomograms
• Risk Factors
• Stroke (diagnosis, drug therapy)
• Thrombolytic Therapy (methods)
• Ticlopidine (analogs & derivatives, therapeutic use)
• Tissue Plasminogen Activator (therapeutic use)